BeOne Medicines Ltd.SSE: 688235

Announcement on Voluntary Disclosure of European Commission's Approval of Baize'an (Tislelizumab Injection) for First-line and Second-line Treatment of Three Non-small Cell Lung Cancer Indications

· Issued by BeOne Medicines Ltd. via Shanghai Stock Exchange

Filed with SSE ·

On 6ix: 6ix.com/news/announcement-on-voluntary-disclosure-of-european-commissions-approval-of-baizean-tislelizumab-injection-for-first-line-and-second-line-treatment-of-three-non-small-cell-lung-cancer-indications


Announcement on Voluntary Disclosure of European Commission's Approval of Baize'an (Tislelizumab Injection) for First-line and Second-line Treatment of Three Non-small Cell Lung Cancer Indications

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

BeOne Medicines Ltd. on 6ix

Earlier from BeOne Medicines

Later from BeOne Medicines

All BeOne Medicines news releases